PSGL-1 blockade delays relapse to BRAF/MEK inhibition in cutaneous melanoma
It is demonstrated that dual inhibition of BRAF/MEK and PSGL-1 elicits durable tumor control in a preclinical model of PD-1-refractory cutaneous melanoma, and antibody-mediated blockade of PSGL-1, in combination with BRAF/MEK inhibition, yields superior anti-tumor activity compared with either monotherapy.